Full Press Release Details
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therapeutic technology platform, announced today that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual healthcare conferences in September.
Citi’s 15th Annual BioPharma Virtual Conference
Date: Thursday, September 10, 2020
H.C. Wainwright 22nd Annual Global Investment Conference
Date: Tuesday, September 15, 2020
Time: 12:00 p.m. ET
A live audio webcast of the H.C. Wainwright presentation will be available through the Events and Presentations page of CytomX's website at www.CytomX.com. An archived replay will be available for 90 days following the event.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are developing a novel class of investigational antibody therapeutics, based on our Probody® technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas and Bristol Myers Squibb.
Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.
Investor and Media Contact: